HUTCHMED Advances Surufatinib Combo into Phase III Trial for Metastatic Pancreatic Cancer in China

HUTCHMED (China) ( (HK:0013) ) just unveiled an update.

HUTCHMED has initiated the Phase III stage of an ongoing Phase II/III clinical trial in China testing a four-drug combination—surufatinib, camrelizumab, nab-paclitaxel and gemcitabine—as a first-line therapy for treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma, a highly lethal cancer with limited effective options. Building on encouraging Phase II data that showed a substantial improvement in progression-free survival, response rates and disease control compared with standard chemotherapy alone, the expansion to approximately 400 additional patients in Phase III underscores the company’s bid to position surufatinib at the core of a potentially new standard treatment regimen in pancreatic cancer and could meaningfully enhance its oncology franchise in the Chinese market if the overall survival endpoint and safety profile remain favorable.

The most recent analyst rating on (HK:0013) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.

More about HUTCHMED (China)

HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. It brings in-house discovered drug candidates to market globally, with three medicines already marketed in China and one of them also approved in the US, Europe and Japan; its portfolio includes surufatinib (SULANDA®), an oral angio-immuno kinase inhibitor for oncology indications.

YTD Price Performance: 1.55%

Average Trading Volume: 4,879,999

Technical Sentiment Signal: Sell

Current Market Cap: HK$18.27B

See more data about 0013 stock on TipRanks’ Stock Analysis page.